Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.47 |
| ▸ | YAP1 | P46937 | 1/20 | 0.47 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.47 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | SOD1 | P00441 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1570200 | 0.98 | SLC6A4 (0.48) | SLC6A4SLC6A3ALDH1A1KMT2ANPC1 | |
| SCHEMBL3667550 | 0.87 | ALDH1A1 (0.48) | SLC6A4SLC6A3ALDH1A1NPC1RAB9A | |
| SCHEMBL9866388 | 0.86 | KDM4E (0.49) | SLC6A4SLC6A3ALDH1A1KMT2ANPC1 | |
| SCHEMBL9808062 | 0.85 | TEAD1 (0.53) | ALDH1A1KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL9083039 | 0.85 | KDM4E (0.51) | SLC6A4SLC6A3ALDH1A1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL2345711 | 0.85 | KDM4E (0.47) | SLC6A4SLC6A3ALDH1A1KMT2ANPC1 | |
| SCHEMBL4025742 | 0.83 | HDAC3 (0.54) | ALDH1A1KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL9808069 | 0.80 | KDM4E (0.55) | ALDH1A1KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL9808024 | 0.80 | KDM4E (0.59) | ALDH1A1KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL23916317 | 0.78 | MAPK1 (0.48) | ALDH1A1KMT2ANPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676926-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS | ThirtyFiveBio Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024184650-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS. | ThirtyFiveBio Limited (GB) | 2024-09-12 | — | — | WO | disclosed |
| EP-3184171-B1 | PHOSPHINYL AMIDINE COMPOUNDS, METAL COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS | CHEVRON PHILLIPS CHEMICAL CO LP (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10144752-B2 | Phosphinyl amidine compounds, metal complexes, catalyst systems, and their use to oligomerize or polymerize olefins | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2018-12-04 | — | — | US | disclosed |
| US-20170305945-A1 | Phosphinyl Amidine Compounds, Metal Complexes, Catalyst Systems, and Their Use to Oligomerize or Polymerize Olefins | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2017-10-26 | — | — | US | disclosed |
| US-9732106-B2 | Phosphinyl amidine compounds, metal complexes, catalyst systems, and their use to oligomerize or polymerize olefins | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2017-08-15 | — | — | US | disclosed |
| EP-3184171-A1 | PHOSPHINYL AMIDINE COMPOUNDS, METAL COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS | Chevron Phillips Chemical Company LP (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2593102-B1 | OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2519532-B1 | PHOSPHINYL AMIDINE COMPOUNDS, METAL COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS | CHEVRON PHILLIPS CHEMICAL CO LP (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2555772-B1 | OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME (US) | 2017-01-11 | — | — | EP | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | CAMERON KIMBERLY O (US) | 2002-02-07 | — | — | US | disclosed |
| US-6344485-B1 | Method for treating glaucoma | PFIZER INC. | 2002-02-05 | — | — | US | disclosed |
| US-6288120-B1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. | 2001-09-11 | — | — | US | disclosed |
| EP-1000619-A2 | Method for treating glaucoma | Pfizer Products Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| US-5021431-A | H-1 antagonist, h-2 agonist for treating hypertension, cardiac disease or arterial occlusion | HEUMANN PHARMA GMBH & CO. (DE) | 1991-06-04 | — | — | US | disclosed |
| EP-0199845-B1 | IMIDAZOLYLALKYLGUANIDIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HEUMANN PHARMA GMBH & CO (DE) | 1990-08-01 | — | — | EP | disclosed |
| EP-0199845-A1 | Imidazolylalkylguanidin derivatives, process for their preparation and pharmaceutical compositions containing them | HEUMANN PHARMA GMBH & CO (DE) | 1986-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | SLC6A4 3953/4885SLC6A3 4202/4885ALDH1A1 2216/4885 |
| US-10144752-B2 | Phosphinyl amidine compounds, metal complexes, catalyst systems, and their use to oligomerize or polymerize olefins | NIT2, NCLN, NPM1 | SLC6A4 938/4885SLC6A3 763/4885ALDH1A1 4849/4885 |
| US-20170305945-A1 | Phosphinyl Amidine Compounds, Metal Complexes, Catalyst Systems, and Their Use to Oligomerize or Polymerize Olefins | NIT2, NCLN, NPM1 | SLC6A4 938/4885SLC6A3 763/4885ALDH1A1 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.